Overview
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing, and commercializing next-generation medicines that treat immune-mediated, autoimmune and metabolic diseases. Aldeyra's lead product candidate, reproxalap, is a small molecule RASP (Reactive Aldehyde Species that are Pro-inflammatory) sequestering agent in Phase 2b clinical development for the treatment of dry eye disease, and Phase 3 clinical development for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. Aldeyra is also developing other product candidates for autoimmune and metabolic diseases.